Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression
- 19 November 2015
- journal article
- Published by American Society of Hematology in Blood
- Vol. 126 (21), 2362-2365
- https://doi.org/10.1182/blood-2015-08-663237
Abstract
Key Points The mutational profile of patients with preclinical MDS is distinct from that reported in healthy individuals. In the absence of morphologic disease, mutational analysis can predict those patients at high risk of disease progression.Keywords
This publication has 15 references indexed in Scilit:
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA SequenceNew England Journal of Medicine, 2014
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Age-related mutations associated with clonal hematopoietic expansion and malignanciesNature Medicine, 2014
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and ImpostorsCurrent Hematologic Malignancy Reports, 2012
- Detectable clonal mosaicism from birth to old age and its relationship to cancerNature Genetics, 2012
- Detectable clonal mosaicism and its relationship to aging and cancerNature Genetics, 2012
- Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donorsHaematologica, 2011
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesBlood, 2011